Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials

Frontiers in Medicine

article

Bin Zhao¹  Hong Zhao²  Jiaxin Zhao³ 

[1] The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University;The Third Affiliated Hospital of Harbin Medical University;The Fourth Affiliated Hospital of Harbin Medical University;Heilongjiang Academy of Medical Sciences

关键词: vascular endothelial growth factor receptor 2;    fatal adverse event;    cancer;    ramucirumab;    apatinib;   

DOI  :  10.3389/fmed.2019.00176

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Background/Aim: Agents targeting vascular endothelial growth factor (VEGF) pathway have dramatically improved the outlook of cancer treatment. Meanwhile, it is well-known that they are associated with increases in the risk of fatal adverse events (FAEs). Vascular endothelial growth factor receptor 2 (VEGFR2)-targeted drugs have been approved for the treatment of several malignancies. However, little is known regarding the FAEs induced by VEGFR2-targeted agents across different tumor types and treatment regimens. Methods: We searched PubMed and Embase database from January 1966 to April 2018 for randomized controlled trials (RCTs) to calculate the incidence and relative risks (RRs) of FAE. Results: Seventeen RCTs involving 6,982 subjects with solid tumors were included in this study. The overall incidence of FAEs associated with VEGFR2-targeted agents was 1.7% (95% CI: 0.9–2.4%). Compared with controls, the administration of VEGFR2-targeted agents did not increase the risk of FAEs (RR, 1.29; 95% CI: 0.90–1.86). No significant association was found between FAE and VEGFR2-targeted agents in subgroup analyses based on tumor type, treatment strategy, clinical phase, masking method, median treatment duration, and approval status. Additionally, FAEs occurred in the major organ systems dispersedly. Trial sequential analysis revealed that our results are solid and further studies are unlikely to change this. Conclusions: VEGFR2-targeted agents were not associated with an increased risk of FAEs.

【 授权许可】

CC BY